Efficacy and safety of the second‐generation cryoballoon ablation for the treatment of persistent atrial fibrillation in elderly patients

Autor: Gaëlle Vermeersch, Juan‐Pablo Abugattas, Varnavas Varnavas, Jeroen De Cocker, Bruno Schwagten, Juan Sieira, Carlo deAsmundis, Gian‐Battista Chierchia, Yves De Greef
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Journal of Arrhythmia, Vol 37, Iss 3, Pp 626-634 (2021)
Druh dokumentu: article
ISSN: 1883-2148
1880-4276
DOI: 10.1002/joa3.12531
Popis: Abstract Background It is expected that ablation procedures will be increasingly offered to a more aged population affected with persistent AF (persAF); however, the clinical outcomes of ablation in this specific population are not well described. We aimed to analyze the efficacy and safety of CB‐A in this group of patients compared with a younger cohort. Methods and results Eighty‐three patients with (persAF) aged ≥75 years (group 1; mean age 78.2 ± 3.1 years) and 166 patients also affected with persAF aged 30 seconds) atrial arrhythmias without anti‐arrhythmic medication after a blanking period of 3 months. At 2 years, clinical success was achieved in 108 out of 249 patients (43.4%). Median follow‐up was 24 months (IQR: 18.4‐25.5 months). Older patients suffered from more recurrences than those in the younger cohort ((53/83 patients, 63.9% vs 88/166 patients, 53.0%; P = .03). Thirty (12.0%) patients suffered a complication, but the incidence of complications was not different between both groups. The most frequent complication was transient phrenic nerve injury. Conclusions The global 2 years efficacy of CB‐A PVI in persAF is 43.4%. A lower success rate is achieved in the older patients (36.1%) compared to the younger age group (47.0%). However, the complication rate was not different between age groups.
Databáze: Directory of Open Access Journals
Externí odkaz: